Stifel Nicolaus Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $5.00

Health Catalyst (NASDAQ:HCAT) had its price target decreased by Stifel Nicolaus from $10.00 to $5.00 in a report released on Thursday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Several other research analysts also recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Stephens reissued an “equal weight” rating and set a $7.00 price objective on shares of Health Catalyst in a research report on Thursday. Piper Sandler lowered their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Royal Bank of Canada lowered their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.45.

Health Catalyst Trading Up 6.4 %

Shares of Health Catalyst stock opened at $4.67 on Thursday. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company has a market capitalization of $284.16 million, a P/E ratio of -3.46 and a beta of 1.34. The company’s fifty day moving average is $5.98 and its two-hundred day moving average is $7.24.

Insider Activity at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the sale, the insider now owns 236,950 shares in the company, valued at $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the completion of the sale, the director now owns 74,438 shares of the company’s stock, valued at $519,577.24. This trade represents a 5.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 87,610 shares of company stock worth $664,043 over the last 90 days. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC raised its position in Health Catalyst by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company’s stock worth $37,055,000 after acquiring an additional 944,631 shares during the last quarter. Impax Asset Management Group plc raised its position in Health Catalyst by 7.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after acquiring an additional 195,525 shares during the last quarter. Daventry Group LP raised its position in Health Catalyst by 3.8% during the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock worth $17,742,000 after acquiring an additional 91,878 shares during the last quarter. Primecap Management Co. CA raised its position in Health Catalyst by 1.1% during the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. raised its position in Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after acquiring an additional 861,150 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.